INTEGRATE II
14 Dec 2020
Trial Summary
The purpose of this phase III study is to determine whether regorafenib is effective in prolonging survival in patients with advanced gastro-oesophageal carcinoma.
Acronym:
INTEGRATE II
ACTRN/NCT /ethics:
ACTRN12616000420448
Scientific title:
A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Sponsor / Cooperative group:
The Australasian Gastro-Intestinal Trials Group (AGITG)
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2016-11-01 |
| Anticipated End Date | 2021-12-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruiting |
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Caroline Bampton |
| Recruitment Status | Recruiting |